Thierry Chevallier

Thierry Chevallier

Auto-generated profile, based on publicly available information

Thierry Chevallier

Department of epidemiology, medical statistics and public health, Nimes University Hospital, Univ Montpellier, Nimes, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
julien frandonjulien frandon
julien frandon
EBElsa Bey
Elsa Bey
AHAymeric Hamard
Aymeric Hamard
HMHélène Mohammad
Hélène Mohammad
SGSamia Gonzalez
Samia Gonzalez
SDStéphane Droupy
Stéphane Droupy

1 May 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NHNadine Houédé
Nadine Houédé
TCThierry Chevallier
Thierry Chevallier
FAFrançois Audenet
François Audenet
CTConstance Thibault
Constance Thibault
YNYann Neuzillet
Yann Neuzillet
MRMorgan Rouprêt
Morgan Rouprêt
PURPOSE: After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. PATIENTS AND METHODS: This phase II trial (ClinicalTrials.gov identifier: NCT04617756 ) included patients with nonmetastatic, high-grade UTUC, on the basis of the ureteroscopic biopsy or urine cytology, and/or infiltrative aspect of the renal pelvis/ureteral wall by computed tomography imaging. Before RNU, patients received durvalumab plus gemcitabine/cisplatin (cohort 1) or durvalumab plus gemcitabine/carboplatin (cohort 2) once every 3 weeks for a total of four cycles (cohort choice on the basis of the glomerular filtration rate). The primary objective was the pathologic complete response (ypT0) rate in each cohort. RESULTS: Fifty patients were enrolled between 2021 and 2024 (31 in cohort 1; 19 in cohort 2). Median age was 68 years (range, 38-79), and 59% were men. Forty-five patients received four cycles of treatment, three patients three cycles, and one patient two cycles. Five patients switched to carboplatin during treatment. At surgery (N = 45 patients), rates of pT0 were 13% (4/29) in cohort 1 and 5% (1/19) in cohort 2. Fifty percent (15/29) of patients were pTa/pT1 in cohort 1, and 42% (8/19) in cohort 2. No severe immunotherapy-mediated toxicity was observed. Four patients had chemotherapy-related grade 3 neutropenia, one grade 4; one patient had grade 3 thrombopenia, one grade 4; and four patients had grade 3 anemia. CONCLUSION: Although our negative study did not meet its primary end point in either cohort, the combination of durvalumab and platin-based chemotherapy, especially cisplatin, showed promising results in terms of downstaging. The safety profile was good and the surgical risk was not increased.

7 August 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
FTFatah Tidadini
Fatah Tidadini
AEAnne-cecile Ezanno
Anne-cecile Ezanno
BTBertrand Trilling
Bertrand Trilling
AAAdeline Aime
Adeline Aime
JAJulio Abba
Julio Abba
CACatherine Arvieux
Catherine Arvieux



24 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JVJérome Vialaret
Jérome Vialaret
AFAnne Filleron
Anne Filleron
RCRenaud Cezar
Renaud Cezar
MPManuela Pastore
Manuela Pastore
MFMarc Fila
Marc Fila
TTTu-Anh Tran
Tu-Anh Tran
Background: IgA vasculitis (IgAV) is the most common systemic vasculitis in children, and its prognosis is largely determined by renal involvement (IgAV nephritis). No routine blood test identifies IgAV or stratifies the risk of nephritis, although aberrant O-glycosylation of the IgA1 hinge region is central to its pathogenesis. We developed a mass-spectrometry assay to profile IgA1 hinge O-glycoforms and define signatures of disease activity and renal involvement. Methods: IgA was affinity-purified from 5 µL of plasma from 91 children (27 with acute IgAV, 26 in remission, and 38 age-matched healthy controls; 24 with and 29 without nephritis), trypsin-digested, and hinge-region O-glycopeptides were quantified by LC-MS. Sixty-nine glycoforms were normalized to a total-IgA1 tryptic peptide. Duplicate measurements showed good analytical repeatability, with a median coefficient of variation of 6%. Groups were compared using Mann–Whitney and Kruskal–Wallis tests (Benjamini– Hochberg FDR). Discrimination was assessed by ROC analysis and cross-validated logistic regression panels. Results: Acute IgAV showed broad remodeling of the hinge glycoform profile (35 glycoforms differed with excellent discrimination (AUC 0.93–0.95) for the best ones), with an increase in low-sialylated, agalactosylated species and a decrease in complex sialylated species. The profile was normalized in remission (no glycoform differed from the controls). Two distinct renal patterns emerged: disease-associated glycoforms already altered without nephritis and renal-specific glycoforms altered only in nephritis (H2N2S1, H3N3S5, H3N4S4, and H4N4S3). A four-marker panel discriminated nephritis among IgAV children with a cross-validated AUC of 0.86 (IC 95 % 0.75–0.94). Conclusions: A single mass-spectrometry assay, from a small blood volume, captures an IgAV-associated IgA1 hinge O-glycoform signature that normalizes in remission, together with a distinct renal involvement associated signature. These findings identify candidate IgA1 O-glycoform signatures associated with IgAV activity and documented renal involvement. Prospective longitudinal studies are required to determine whether the renal-associated panel can predict subsequent nephritis.